NASDAQ:COGT Cogent Biosciences Q1 2025 Earnings Report $33.41 -0.67 (-1.97%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$33.78 +0.38 (+1.12%) As of 09/11/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cogent Biosciences EPS ResultsActual EPS-$0.52Consensus EPS -$0.56Beat/MissBeat by +$0.04One Year Ago EPSN/ACogent Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACogent Biosciences Announcement DetailsQuarterQ1 2025Date5/6/2025TimeBefore Market OpensConference Call DateTuesday, May 6, 2025Conference Call Time8:00AM ETUpcoming EarningsCogent Biosciences' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 2, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cogent Biosciences Earnings HeadlinesCogent Biosciences, Inc. (NASDAQ:COGT) Receives $51.56 Consensus Price Target from AnalystsSeptember 11 at 3:45 AM | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Lowered to "Sell" Rating by Wall Street ZenSeptember 5, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 13 at 1:00 AM | Stansberry Research (Ad)Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCienciaSeptember 2, 2026 | marketscreener.comMCogent Biosciences: 3 NDAs Create A Time-To-Market MoatAugust 27, 2026 | seekingalpha.comCogent Biosciences, Inc. (COGT)August 14, 2026 | finance.yahoo.comSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses its research platform to discover and advance targeted therapies designed to address the underlying drivers of serious medical conditions. Cogent’s lead product candidate is bezuclastinib, an oral, highly selective tyrosine kinase inhibitor designed to target the KIT D816V mutation and other KIT alterations. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both non-advanced and advanced forms of the disease. Cogent Biosciences is headquartered in Boulder, Colorado, and conducts its clinical development activities through studies involving patients and research sites in multiple regions. The company is led by Andrew Robbins, who serves as president and chief executive officer.View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
